DrugPatentWatch Database Preview

VIBATIV Drug Profile

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Vibativ, and what generic alternatives are available?

Vibativ is a drug marketed by Theravance Biopharma and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and twenty-four patent family members in thirty-five countries.

The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

Summary for VIBATIV

International Patents:	124
US Patents:	11
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	11
Clinical Trials:	13
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIBATIV
DailyMed Link:	VIBATIV at DailyMed

Pharmacology for VIBATIV

Ingredient-type	Lipoglycopeptides
Drug Class	Lipoglycopeptide Antibacterial

Synonyms for VIBATIV

0701472ZG0

372151-71-8

560130-42-9

AC1MIWRX

AM006875

Arbelic

CHEBI:71226

CHEBI:71229

CHEMBL3301680

CHEMBL507870

D02IJB

D06057

D0B9JO

DB06402

HSDB 8194

LS-192933

N(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin

SCHEMBL8287015

SIB-1533A

T-1455

Td 6424

TD-6424

Telavancin

Telavancin [INN]

Telavancin HCl

Telavancin Hydrochloride

Telavancin hydrochloride (USAN)

Telavancin hydrochloride [USAN]

Telavancin, Antibiotic for Culture Media Use Only

telavancina

telavancine

telavancinum

UNII-0701472ZG0

UNII-XK134822Z0

Vancomycin, N3'-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride

Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-

Vibativ (TN)

XK134822Z0

US Patents and Regulatory Information for VIBATIV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;IV (INFUSION)	022110-001	Sep 11, 2009		DISCN	Yes	No			Y	Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;IV (INFUSION)	022110-002	Sep 11, 2009		RX	Yes	Yes			Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;IV (INFUSION)	022110-001	Sep 11, 2009		DISCN	Yes	No			Y
Theravance Biopharma	VIBATIV	telavancin hydrochloride	POWDER;IV (INFUSION)	022110-001	Sep 11, 2009		DISCN	Yes	No

  Purchase this report

or, see our see our flat-rate plans

Non-Orange Book US Patents for VIBATIV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,903,070	Glycopeptide carboxy-saccharide derivatives
6,828,299	Polyhydroxy glycopeptide derivatives
6,620,781	Glycopeptide carboxy-saccharide derivatives
8,859,506	Glycopeptide phosphonate derivatives

  Purchase this report

or, see our see our flat-rate plans

International Patents for VIBATIV

Country	Document Number	Estimated Expiration
Canada	2726967
Yugoslavia	96902
European Patent Office	1278549
Australia	5930601

Supplementary Protection Certificates for VIBATIV

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2011	Austria		PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
908	Luxembourg		91908, EXPIRES: 20260501
C/GB11/056	United Kingdom		PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
2011 00033	Denmark		PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID